Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Vaccine ; 10 Suppl 1: S110-3, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1362031

RESUMEN

Two inactivated hepatitis A virus (HAV) candidate vaccine strain were tested, derived from strains CLF and HM175. Neither vaccine increased liver enzymes levels and reactogenicity was similar to that observed with other alum-absorbed products. Antibody responses were dose-dependent and protection against HAV can be presumed to last for at least three years. All persons receiving 720 ELISA units (El.U) of the CLF vaccine seroconverted after one dose. For the HM175 vaccine, anti-HAV persisted until month 12 after injections at months 0 and 1, suggesting that the third dose of vaccine could be given at any time from month 6 to 12. A double dose of HM175 vaccine (1440 El.U) given as a single bolus resulted in 100% seroconversion by day 14 with a geometric mean anti-HAV level of 121 mIU/ml. This implies that rapid protection can be induced using large doses of inactivated HAV vaccine should time constraints dictate such an approach.


Asunto(s)
Anticuerpos Antihepatitis/biosíntesis , Hepatovirus/inmunología , Vacunas contra Hepatitis Viral/inmunología , Adulto , Alanina Transaminasa/metabolismo , Fosfatasa Alcalina/metabolismo , Bilirrubina/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Anticuerpos de Hepatitis A , Vacunas contra la Hepatitis A , Anticuerpos Antihepatitis/sangre , Humanos , Esquemas de Inmunización , L-Lactato Deshidrogenasa/metabolismo , Hígado/enzimología , Masculino , Suiza , Vacunas de Productos Inactivados/inmunología , Vacunas contra Hepatitis Viral/administración & dosificación , Vacunas contra Hepatitis Viral/efectos adversos , gamma-Glutamiltransferasa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA